Calendario›SNY›Dupilumab · ProMEAL

Dupilumab · ProMEAL

A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

Ensayo de Sanofi en Eosinophilic Esophagitis (del registro, en inglés).

Fase

no aplica

Estado

Reclutando pacientes

Participantes

150

previstos

Centros

15

Fin del objetivo primario

jun 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en may 2025.

Qué mide

Descriptive statistical analysis of medical history characteristics (del registro, en inglés) (en el inicio)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with respect to their medical history, socio-demographic and disease characteristics, comorbidities (including type 2 inflammatory and atopic conditions), concomitant therapies and prior EoE treatments. Furthermore, this NIS aims to describe the long-term effectiveness of dupilumab for the treatment of EoE as assessed by the treating physician and reported by the patient, and its effect on health-related quality of life (HRQoL) during an individual observational period of two years. In addition, data on real-world use patterns and long-term safety data of dupilumab treatment for EoE will be collected.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06695897), actualizada en sep 2026.